Department of Obstetrics and Gynecology, Duke University, Durham, North Carolina.
Gastroenterology. 2013 Nov;145(5):1076-87. doi: 10.1053/j.gastro.2013.07.047. Epub 2013 Jul 31.
BACKGROUND & AIMS: Cirrhosis and liver cancer are potential outcomes of advanced nonalcoholic fatty liver disease (NAFLD). It is not clear what factors determine whether patients will develop advanced or mild NAFLD, limiting noninvasive diagnosis and treatment before clinical sequelae emerge. We investigated whether DNA methylation profiles can distinguish patients with mild disease from those with advanced NAFLD, and how these patterns are functionally related to hepatic gene expression.
We collected frozen liver biopsies and clinical data from patients with biopsy-proven NAFLD (56 in the discovery cohort and 34 in the replication cohort). Samples were divided into groups based on histologic severity of fibrosis: F0-1 (mild) and F3-4 (advanced). DNA methylation profiles were determined and coupled with gene expression data from the same biopsies; differential methylation was validated in subsets of the discovery and replication cohorts. We then analyzed interactions between the methylome and transcriptome.
Clinical features did not differ between patients known to have mild or advanced fibrosis based on biopsy analysis. There were 69,247 differentially methylated CpG sites (76% hypomethylated, 24% hypermethylated) in patients with advanced vs mild NAFLD (P < .05). Methylation at fibroblast growth factor receptor 2, methionine adenosyl methyltransferase 1A, and caspase 1 was validated by bisulfite pyrosequencing and the findings were reproduced in the replication cohort. Methylation correlated with gene transcript levels for 7% of differentially methylated CpG sites, indicating that differential methylation contributes to differences in expression. In samples with advanced NAFLD, many tissue repair genes were hypomethylated and overexpressed, and genes in certain metabolic pathways, including 1-carbon metabolism, were hypermethylated and underexpressed.
Functionally relevant differences in methylation can distinguish patients with advanced vs mild NAFLD. Altered methylation of genes that regulate processes such as steatohepatitis, fibrosis, and carcinogenesis indicate the role of DNA methylation in progression of NAFLD.
肝硬化和肝癌是晚期非酒精性脂肪性肝病(NAFLD)的潜在后果。目前尚不清楚哪些因素决定了患者将发展为轻度或晚期 NAFLD,这限制了在出现临床后果之前进行非侵入性诊断和治疗。我们研究了 DNA 甲基化谱是否可以区分轻度疾病患者和晚期 NAFLD 患者,以及这些模式如何与肝基因表达功能相关。
我们收集了经活检证实的 NAFLD 患者的冷冻肝活检和临床数据(发现队列 56 例,复制队列 34 例)。根据纤维化的组织学严重程度将样本分为 F0-1(轻度)和 F3-4(晚期)组。确定 DNA 甲基化谱,并与来自同一活检的基因表达数据相结合;在发现和复制队列的亚组中验证差异甲基化。然后,我们分析了甲基组和转录组之间的相互作用。
根据活检分析,已知患有轻度或晚期纤维化的患者的临床特征没有差异。晚期与轻度 NAFLD 患者相比,有 69247 个差异甲基化 CpG 位点(76%低甲基化,24%高甲基化)(P <.05)。通过亚硫酸氢盐焦磷酸测序验证了成纤维细胞生长因子受体 2、蛋氨酸腺苷转移酶 1A 和半胱氨酸蛋白酶 1 的甲基化,在复制队列中得到了重现。在晚期 NAFLD 样本中,许多组织修复基因呈低甲基化和高表达,某些代谢途径(包括 1 碳代谢)中的基因呈高甲基化和低表达。
功能相关的甲基化差异可以区分晚期与轻度 NAFLD 患者。调节脂肪性肝炎、纤维化和癌变等过程的基因的甲基化改变表明 DNA 甲基化在 NAFLD 进展中的作用。